Previously, trastuzumab was mainly used alone or in combination with chemotherapeutic agents to treat HER2-positive breast cancer, but is now also used in neoadjuvant and adjuvant therapies aimed at shrinking the size of tumors or reducing the risk of recurrence (Swain et al., 2023). The gene discussed is ERBB2; the disease is breast carcinoma.